Kings Point Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Kings Point Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-40	Closed	-$25K	–	643
2021 Q4	$25K	Sell	40 -10	-20%	-$6.15K	﹤0.01%	495
2021 Q3	$30K	Hold	50	–	–	﹤0.01%	436
2021 Q2	$28K	Sell	50 -20	-29%	-$10.1K	﹤0.01%	422
2021 Q1	$33K	Hold	70	–	–	﹤0.01%	391
2020 Q4	$34K	Hold	70	–	–	﹤0.01%	368
2020 Q3	$39K	Sell	70 -10	-13%	-$6.06K	﹤0.01%	331
2020 Q2	$50K	Hold	80	–	–	0.01%	279
2020 Q1	$39K	Sell	80 -20	-20%	-$8.25K	0.01%	305
2019 Q4	$38K	Sell	100 -50	-33%	-$16.8K	0.01%	348
2019 Q3	$42K	Buy	+150	New	+$44.4K	0.01%	317

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kings Point Capital Management's REGN Position: Q1 2022 in Review

Kings Point Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 40 shares — an estimated $25K sold.

Kings Point Capital Management first reported a position in REGN in Q3 2019 and held it in 10 quarters. The position peaked at $50K in Q2 2020. 1,094 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

Kings Point Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Kings Point Capital Management sold 40 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $25K.
Kings Point Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2019 and held it in 10 quarters.
Kings Point Capital Management's Regeneron Pharmaceuticals position peaked at $50K in Q2 2020.
1,094 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Kings Point Capital Management's 13F filing for Q1 2022, filed 13 May 2022.